Participation in Brighters share issue.

On November 18, 2019, Brighter AB announced a share issue to accelerate the commercialization of Actiste Diabetes Management as a Service.

Over-subscribing is not possible - the only way to participate in the issue is to already hold subscription rights, or by purchasing subscription rights in the trading that starts today.

Trading in subscription rights will continue from December 18, 2019 through January 8, 2020. The subscription period in the offering will run through January 10, 2020.

Prospectus is available on the company's website, https://brighter.se/

For further information, please contact:

Truls Sjöstedt, Executive Chairman of the Board
Telephone: +46 729 99 38 60   
Email: truls.sjostedt@brighter.se

About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – improving quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. https://brighter.se/

Brighter’s Certified Adviser on Nasdaq OMX First North is Eminova Fondkommission AB, +46 (0)8 – 684 211 10, adviser@eminova.se, www.eminova.se. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.